In Washington, DC and state capitals around the country, Lupus Foundation of America advocates tell their stories and urge their elected officials to support policies that improve the lives of people ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...

A National Resource Center on Lupus library of downloadable fact sheets and toolkits to help people with lupus and their care partners learn more about living with lupus.

The Lupus & You: Empowerment conference is an experience that celebrates, inspires, supports, and uplifts lupus warriors, care partners, family, and friends. During this empowering day, attendees will ...

A new study identifies eight domains of active systemic #lupus erythematosus for defining meaningful treatment response in lupus clinical trials.

In this episode of our podcast, we explore the intersection of menopause and lupus, highlighting the unique challenges faced by women with lupus during this significant life transition.

The potential elimination of lupus programs across government would undermine the incredible progress and significant investment that has been made in lupus over the past three decades.

A lupus flare, also called a flare up, is when your lupus becomes more active and makes you feel sick. The following video describes flares, their triggers, as well as some tips to help you avoid them ...

Mesenchymal stem cells (MSCs) are unique adult stem cells with immunosuppressive properties that also may play a key role in preventing autoimmunity. In a new study, researchers identified metabolic ...

In a new study, researchers explored experiences, perceptions, and health effects of a newly developed healthy lifestyle intervention for people with systemic lupus erythematosus (SLE).

Today at the American College of Rheumatology (ACR) Annual Meeting, Convergence 2024, the ACR released a summary of a new guideline for the screening, treatment and management of lupus nephritis ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).